Related Experiment Video
Updated: Aug 18, 2026

Detection of Alternative Splicing During Epithelial-Mesenchymal Transition
Published on: October 9, 2014
[Implication of alternative splice transcripts of caspase-3 and survivin in chemoresistance]
Frédérique Vegran1, Romain Boidot, Claire Oudin
1Laboratoire de génétique moléculaire, Centre anticancéreux G.F. Leclerc, Inserm U517, 1, rue du Professeur Marion, 21079 Dijon Cedex.
Abstract:
Recent studies have shown that resistance to apoptosis may contribute to chemoresistance. Alteration of caspases, such as caspase-3, results on decreased apoptosis. Genes of IAP (inhibitor of apoptosis proteins) family, such as survivin, were also implicated in tumor development where they are mutated or have deregulated expression. Initial studies revealed strong survivin expression in several fetal tissues and some proliferating adult tissues, whereas no survivin expression was detected in a range of adult tissues. Although the factors at the origins on survivin re-expression in tumors are still unknown, the anti-apoptotic function of survivin is mediated in part by inhibiting caspase-3 activity. Recently, functionally divergent splice variants resulting from alternative splicing, with apoptotic (for caspase-3) or anti-apoptotic (for survivin) opposite activities have been described. The alternative splice variant, caspase-3s results from exon 6 deletion and shows antagonist of apoptotic property of caspase-3. Three alternative splice variants of survivin (survivin-DeltaEx3, survivin-2B and survivin-3B) differing in their anti-apoptotic properties were reported. While the anti-apoptotic effect of survivin-DeltaEx3 is preserved, survivin-2B has lost its anti-apoptotic potential and may act as a naturally occurring antagonist of survivin and survivin-DeltaEx3. At present, little is known about properties of survivin-3B. Several evidences indicate that in several cancers, the ratio of splice variants is significantly altered, and modifications of splicing pathways have been developed for cancer treatment. Recent investigations have shown that expression of alternative splice variants of caspase-3 and of survivin were also altered in many human cancers, and that variations in their expression were associated with tumor progression and chemoresistance. In this article, we describe recent data concerning alternative splice variants of these two proteins.
Insights
Alternative splice variants of caspase-3 and survivin proteins are altered in human cancers, impacting tumor progression and chemoresistance. Understanding these variants is crucial for developing novel cancer treatments.
Area of Science:
- Molecular Biology
- Cancer Biology
- Genetics
Background:
- Resistance to apoptosis is linked to chemoresistance in cancer.
- The inhibitor of apoptosis proteins (IAP) family, including survivin, and caspases like caspase-3, play critical roles in apoptosis regulation.
- Deregulation and mutations in these proteins are implicated in tumor development.
Purpose of the Study:
- To review recent data on alternative splice variants of caspase-3 and survivin.
- To highlight the altered expression of these variants in human cancers.
- To discuss the association between variant expression and tumor progression/chemoresistance.
Main Methods:
- Literature review of recent studies on caspase-3 and survivin splice variants.
- Analysis of data linking variant expression to cancer characteristics.
- Focus on alternative splicing mechanisms and their functional consequences.
Main Results:
- Alternative splice variants of caspase-3 (e.g., caspase-3s) and survivin (e.g., survivin-DeltaEx3, survivin-2B, survivin-3B) exhibit divergent apoptotic or anti-apoptotic activities.
- Expression of these variants is altered in various human cancers.
- Modified ratios of splice variants correlate with tumor progression and chemoresistance.
Conclusions:
- Alternative splicing of caspase-3 and survivin generates functionally distinct proteins.
- Altered expression patterns of these splice variants are significant in human cancers.
- Targeting alternative splicing pathways may offer novel therapeutic strategies for cancer treatment.
Related Concept Videos
RNA Splicing
Alternative RNA Splicing
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
Caspases
Treatment Resistant Cancers
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...

